Savara Pharma (SVRA) - מקדם חוב לטווח ארוך להון

Savara Inc. (SVRA) enjoys high authority among physicians treating rare respiratory pathologies due to its focus on developing life-saving medications. The production facility, featuring modern sterile zones, operates seamlessly to ensure drug output. The separate_debt_long_eq metric stands at 0.22. The stock's price history demonstrates the potential of the company as it develops a unique inhalation therapy method for patients with APAP.

This indicator measures the proportion of long-term liabilities within the equity structure, determining the degree of financial leverage and the company's resilience to interest rate fluctuations. Analyzing long-term debt relative to equity allows for an assessment of how effectively Savara Inc. (SVRA) finances the development of exclusive orphan drugs, converting long-term loans into high-margin assets with guaranteed market demand.